Biofrontera Inc.

NasdaqCM BFRI

Biofrontera Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -0.63

Biofrontera Inc. Price to Earnings Ratio (P/E) is -0.63 on January 14, 2025, a -29.25% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Biofrontera Inc. 52-week high Price to Earnings Ratio (P/E) is -0.17 on February 14, 2024, which is 73.93% above the current Price to Earnings Ratio (P/E).
Biofrontera Inc. 52-week low Price to Earnings Ratio (P/E) is -0.80 on August 19, 2024, which is -26.69% below the current Price to Earnings Ratio (P/E).
Biofrontera Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.50.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: BFRI

Biofrontera Inc.

CEO	Dr. Hermann Luebbert Ph.D.
IPO Date	Oct. 29, 2021
Location	United States
Headquarters	120 Presidential Way
Employees	83
Sector	Health Care
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies

Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Key trends

Past 5 years